Kyverna Therapeutics outperforms Sana Biotechnology in revenue, earnings, potential upside, and consensus ratings.

Kyverna Therapeutics (NASDAQ: KYTX) outperforms Sana Biotechnology (NASDAQ: SANA) in terms of revenue, earnings, potential upside, and consensus ratings, while Sana Biotechnology has higher institutional ownership. Kyverna focuses on autoimmune diseases, with a lead product in Phase I trials, while Sana develops engineered cell therapies for various areas. Kyverna has a consensus price target of $42.75 and a potential upside of 177.24%, compared to Sana's $11.67 target and 33.64% upside.